Zydus Cadila has received the final approval from the US Food and Drug Administration (FDA) to market Acetazolamide ER Capsules (US RLD-Diamox). It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
Acetazolamide is a potent carbonic anhydrase inhibitor. Acetazolamide ER capsules are used to treat certain types of glaucoma (caused by increased ocular pressure) and to treat or prevent altitude sickness (acute mountain sickness).
The group now has 246 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.
Cadila Healthcare Ltd share price is currently at Rs357, up Rs4.65, or 1.32%, from its previous close of Rs352.35 on the BSE.
The scrip opened at Rs353.10 and has touched a high and low of Rs358.75 and Rs353.10, respectively. So far, 5,82,199 (NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs36,071.57cr.